Empowered Funds LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the second quarter, HoldingsChannel.com reports. The fund bought 108,041 shares of the biotechnology company’s stock, valued at approximately $8,806,000.
Several other hedge funds have also bought and sold shares of ARWR. Tsfg LLC acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $25,000. Optiver Holding B.V. boosted its stake in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares during the period. Versant Capital Management Inc increased its holdings in shares of Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC raised its stake in Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $29,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This represents a 5.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.60% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on ARWR
Arrowhead Pharmaceuticals Stock Down 4.2%
Shares of ARWR opened at $84.91 on Friday. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $21.61 and a 12 month high of $95.49. The firm’s 50 day moving average is $83.64 and its 200-day moving average is $73.54. The stock has a market capitalization of $11.96 billion, a PE ratio of -37.74 and a beta of 1.27.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same quarter last year, the firm posted ($1.26) earnings per share. The company’s quarterly revenue was up 171.0% on a year-over-year basis. Equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company’s pipeline includes multiple candidates in various stages of development.
Read More
- Five stocks we like better than Arrowhead Pharmaceuticals
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
